| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 05/06/2004 | US20040086567 Dissolution |
| 05/06/2004 | US20040086565 Orally administering to once prior to sleep a dosage formulation comprising a biologically inert pellet having a drug layer, an outer rate controlling layer |
| 05/06/2004 | US20040086562 Orally administering to a patient a spaced drug delivery system, wherein first therapeutically active agent is released immediately and second therapeutically active agent is released as a pulse at predetermined time after administration |
| 05/06/2004 | US20040086561 For preventing oral abuse of an oral opioid formulation |
| 05/06/2004 | US20040086559 Pharmaceutical tablet comprising paroextine mesylate |
| 05/06/2004 | US20040086556 Transdermal and topical administration of local anesthetic agents using basic enhancers |
| 05/06/2004 | US20040086555 Plaster containing felbinac |
| 05/06/2004 | US20040086554 Anti-inflammatory, analgesic plaster containing felbinac for the purpose of curing lumbago, myalgia, periarthritis, and so on |
| 05/06/2004 | US20040086553 Foods and beverages for whitening and orally administered whitening agents |
| 05/06/2004 | US20040086551 Fentanyl suspension-based silicone adhesive formulations and devices for transdermal delivery of fentanyl |
| 05/06/2004 | US20040086540 Topically administering to an area on the subject where ectoparasites are present a composition comprising a fatty acid ester and at least 20% cyclic siloxane |
| 05/06/2004 | US20040086537 Comprises a chymase inhibitor as the active ingredient |
| 05/06/2004 | US20040086536 Comprising an anticholinergic agent and an NO donor as the active ingredients |
| 05/06/2004 | US20040086514 Based on the finding of a specific Helicobacter pylori receptor in the human gastric epithelium; a glycolipid, lactotetraosylceramide, exclusively found in the human gastrointestinal tract |
| 05/06/2004 | US20040086506 Polyvalent immunogen |
| 05/06/2004 | US20040086498 Cancer therapy |
| 05/06/2004 | US20040086496 Composition derived from biological materials and method of use and preparation |
| 05/06/2004 | US20040086495 Method for the treatment of arteriosclerosis |
| 05/06/2004 | US20040086487 Prevention or the treatment of congestive heart failure or myocardial ishchemia by administering a sphingosine kinase, or an analogue, fragment, or derivative thereof |
| 05/06/2004 | US20040086485 Viral vector sequences in plasmid form delivered in-vivo to generate vector producing cells |
| 05/06/2004 | US20040086482 Trialkalnolamines that have been esterified with organic acids including long chain fatty acids and reacted with diisocyanates |
| 05/06/2004 | US20040086479 Can be chemically modified for different biomedical applications such as tissue engineering applications, wound management, contrast agents vehicles, drug delivery vehicles, etc. |
| 05/06/2004 | US20040086471 Compositions for darkening the skin and/or hair |
| 05/06/2004 | US20040086469 Protectant for UV-induced skin damage |
| 05/06/2004 | US20040086465 Aerosol suspension formulations which are free of chlorofluorocarbons comprising mometasone furoate, a dry powder surfactant and HFA 227, |
| 05/06/2004 | US20040086464 Medicaments |
| 05/06/2004 | US20040086462 Radio-opaque polymer biomaterials |
| 05/06/2004 | US20040086461 Radio-opaque polymer biomaterials |
| 05/06/2004 | US20040086458 Radio-opaque polymer biomaterials |
| 05/06/2004 | US20040086453 Compositions, methods, apparatuses, and systems for singlet oxygen delivery |
| 05/06/2004 | EP1416052A1 Process for producing 1,4-dihydroxy-2-naphthoic acid |
| 05/06/2004 | EP1416048A1 Nucleic acid participating in the formation of presenilin-2-gene exon 5-;defective splicing variant |
| 05/06/2004 | EP1415992A1 Diamine derivatives |
| 05/06/2004 | EP1415990A1 Diazepan derivatives useful as factor X inhibitor |
| 05/06/2004 | EP1415987A1 Nitrogenous aromatic ring compounds |
| 05/06/2004 | EP1415986A1 Spiro compounds |
| 05/06/2004 | EP1415984A1 Aryloxyarylsulfonylamino hydroxamic acid derivatives |
| 05/06/2004 | EP1415982A1 Halogenated amidino amino acid derivatives useful as nitric oxide synthase inhibitors |
| 05/06/2004 | EP1415668A1 Remedies for brain ischemic diseases |
| 05/06/2004 | EP1415667A1 Pancreatic juice secretion regulators comprising lpa receptor controller |
| 05/06/2004 | EP1415659A1 BAFF, inhibitors thereof and their use in the modulation of the B-cell response |
| 05/06/2004 | EP1415657A1 Remedies |
| 05/06/2004 | EP1415654A1 Enhancedly-solubilized beta-hydroxy acids and higher potency skin peels formulated therefrom |
| 05/06/2004 | EP1415653A2 Use of progesterone or an agonist thereof for the inhibition of steroid synthesis |
| 05/06/2004 | EP1415652A2 Composition comprising phosphodiesterase inhibitors for the treatment of sexual dysfunction |
| 05/06/2004 | EP1415651A1 Preventives/remedies for cholinergic neuropathy |
| 05/06/2004 | EP1415650A1 Nutritional composition for the prevention and treatment of cachexia and anorexia |
| 05/06/2004 | EP1415649A1 Transdermal therapeutic system comprising oxybutynin |
| 05/06/2004 | EP1415647A1 "Long-acting beta-2 agonists ultrafine formulations" |
| 05/06/2004 | EP1415645A2 Composition in the form of an oil-in-water emulsion and its cosmetic uses |
| 05/06/2004 | EP1415549A1 Synergistic antioxidant combination of tocols and polyphenols |
| 05/06/2004 | EP1414996A1 Methods for genetic modification of hematopoietic progenitor cells and uses of the modified cells |
| 05/06/2004 | EP1414964A2 Vegf isoform |
| 05/06/2004 | EP1414961A2 Novel oligoribonucleotide derivatives for the targeted inhibition of gene expression |
| 05/06/2004 | EP1414937A1 Hops extracts, method for the production and use |
| 05/06/2004 | EP1414865A2 Isolation of glucan particles and uses thereof |
| 05/06/2004 | EP1414851A2 Cellular virus receptors and methods of use. |
| 05/06/2004 | EP1414843A1 Novel dammarane sapogenins, their use as anti-cancer agents, and a process for producing same |
| 05/06/2004 | EP1414841A1 Oligonucleotide-containing pharmacological compositions and their use |
| 05/06/2004 | EP1414837A1 Adenosine a3 receptor agonists |
| 05/06/2004 | EP1414836A2 Process for the preparation of l-ribavirin |
| 05/06/2004 | EP1414830A1 Tumour inhibiting lanthane compounds |
| 05/06/2004 | EP1414828A1 Antitumoral analogs |
| 05/06/2004 | EP1414826A1 Therapeutically useful tetracyclic ligands |
| 05/06/2004 | EP1414825A1 Thienopyrimidinediones and their use in the modulation of autoimmune disease |
| 05/06/2004 | EP1414824A1 Novel anticonvulsant derivative salts |
| 05/06/2004 | EP1414820A1 Non-nucleoside reverse transcriptase inhibitors |
| 05/06/2004 | EP1414819A1 THERAPEUTIC 1H-PYRIDO 4,3-b]INDOLES |
| 05/06/2004 | EP1414817A1 Substituted isoindoles and e use thereof |
| 05/06/2004 | EP1414816A1 Stable polymorph of flibanserin, technical process for its preparation and the use thereof for preparing medicaments |
| 05/06/2004 | EP1414813A1 1,2,4-trioxolane antimalarials |
| 05/06/2004 | EP1414812A1 Hydroxamic acid derivatives |
| 05/06/2004 | EP1414810A2 1,4-disubstituted benzo-fused cycloalkyl urea compounds |
| 05/06/2004 | EP1414809A1 Indane acetic acid derivatives and their use as pharmaceutical agents, intermediates, and method of preparation |
| 05/06/2004 | EP1414808A1 1,2,4-triazin-3,5-diones as gonadotropin-releasing hormone receptor (gnrh) antagonists |
| 05/06/2004 | EP1414807A1 Pyrimidine derivatives as selective inhibitors of cox-2 |
| 05/06/2004 | EP1414806A1 Novel vinyl n-(2-benzoylphenyl)-l-tyrosine derivatives and their use as antidiabetics etc |
| 05/06/2004 | EP1414805A1 Indazole or indole derivatives, their use in human medicine and more particularly in cancerology |
| 05/06/2004 | EP1414804A1 Acylsemicarbazides and their use as cyclin dependent kinase (cdk) inhibitors |
| 05/06/2004 | EP1414802A1 Heteroarylheteroalkylamine derivatives and their use as inhibitors of nitric oxide synthase |
| 05/06/2004 | EP1414801A1 Arylamines for the treatment of conditions associated with gsk-3 |
| 05/06/2004 | EP1414798A2 Ultrashort-acting opioids for transdermal application |
| 05/06/2004 | EP1414797A2 Hepatitis c virus polymerase inhibitors with a heterobicylic structure |
| 05/06/2004 | EP1414796A1 Crystalline forms vi and vii of atorvastatin calcium |
| 05/06/2004 | EP1414795A1 Bicyclic modulators of androgen receptor function |
| 05/06/2004 | EP1414790A1 Substituted n-acyl aniline derivatives, production and use thereof as medicaments |
| 05/06/2004 | EP1414788A1 Naphthylurea and naphthylacetamide derivatives as vanilloid receptor 1 (vr1) antagonists |
| 05/06/2004 | EP1414785A1 Novel vinyl n-(2-benzoylphenyl)-l-tyrosine derivatives and their use as antidiabetics etc |
| 05/06/2004 | EP1414778A1 Novel vinyl carboxylic acid derivatives and their use as antidiabetics etc. |
| 05/06/2004 | EP1414775A2 Novel bicyclic and tricyclic cannabinoids |
| 05/06/2004 | EP1414526A2 Antiangiogenic combination therapy for the treatment of cancer |
| 05/06/2004 | EP1414525A2 2-(3,5-bis-trifluoromethyl-phenyl)-n-[6-(1,1-dioxo-1.lambda.6-thiomorpholin-4-yl)-4-(2-methyl or 4-fluoro-2-methyl substituted)phenyl-pyridin-3-yl]-n-methyl-isobutyramide |
| 05/06/2004 | EP1414523A2 Use of a lactate salt for the treatment and prophylaxis of atherosclerosis |
| 05/06/2004 | EP1414522A2 Carbonic anhydrase inhibitors |
| 05/06/2004 | EP1414500A2 Akt and regulation of ra synovial fibroblast apoptosis |
| 05/06/2004 | EP1414496A1 Oral pharmaceutical composition containing a combinaition of ppar-alpha and a hmg-coa reductase inhibitor |
| 05/06/2004 | EP1414491A2 Methods of inhibiting amyloid toxicity |
| 05/06/2004 | EP1414489A2 Antiallergic pharmaceutical composition |
| 05/06/2004 | EP1414478A2 Inhibition of neurodegeneration |
| 05/06/2004 | EP1414477A2 Repeat sequences of the ca125 gene and their use for diagnostic and therapeutic interventions |